Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification.

El-Sharkawi D, Ali A, Evans CM, Hills RK, Burnett AK, Linch DC, Gale RE.

Leuk Lymphoma. 2014 Jun;55(6):1326-31. doi: 10.3109/10428194.2013.833332. Epub 2013 Oct 9.

PMID:
23952244
2.

ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.

Paschka P, Schlenk RF, Gaidzik VI, Herzig JK, Aulitzky T, Bullinger L, Späth D, Teleanu V, Kündgen A, Köhne CH, Brossart P, Held G, Horst HA, Ringhoffer M, Götze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Döhner H, Döhner K.

Haematologica. 2015 Mar;100(3):324-30. doi: 10.3324/haematol.2014.114157. Epub 2015 Jan 16.

3.

Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.

Pratcorona M, Abbas S, Sanders MA, Koenders JE, Kavelaars FG, Erpelinck-Verschueren CA, Zeilemakers A, Löwenberg B, Valk PJ.

Haematologica. 2012 Mar;97(3):388-92. doi: 10.3324/haematol.2011.051532. Epub 2011 Nov 4.

4.

Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations.

Chou WC, Huang HH, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, Ko BS, Wu SJ, Huang SY, Hsu SC, Chen YC, Huang YN, Chang YC, Lee FY, Liu MC, Liu CW, Tseng MH, Huang CF, Tien HF.

Blood. 2010 Nov 18;116(20):4086-94. doi: 10.1182/blood-2010-05-283291. Epub 2010 Aug 6.

5.

Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.

Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J, Wagner K, Chaturvedi A, Sharma A, Wichmann M, Göhring G, Schumann C, Bug G, Ottmann O, Hofmann WK, Schlegelberger B, Heuser M, Ganser A.

J Clin Oncol. 2011 Jun 20;29(18):2499-506. doi: 10.1200/JCO.2010.33.4938. Epub 2011 May 16.

6.

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

Mendler JH, Maharry K, Radmacher MD, Mrózek K, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD.

J Clin Oncol. 2012 Sep 1;30(25):3109-18. doi: 10.1200/JCO.2011.40.6652. Epub 2012 Jul 2.

7.

Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.

Devillier R, Mansat-De Mas V, Gelsi-Boyer V, Demur C, Murati A, Corre J, Prebet T, Bertoli S, Brecqueville M, Arnoulet C, Recher C, Vey N, Mozziconacci MJ, Delabesse E, Birnbaum D.

Oncotarget. 2015 Apr 10;6(10):8388-96.

8.

Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.

Ohgami RS, Ma L, Merker JD, Gotlib JR, Schrijver I, Zehnder JL, Arber DA.

Mod Pathol. 2015 May;28(5):706-14. doi: 10.1038/modpathol.2014.160. Epub 2014 Nov 21.

9.

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrózek K, Nicolet D, Whitman SP, Wu YZ, Schwind S, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD.

Blood. 2011 Dec 22;118(26):6920-9. doi: 10.1182/blood-2011-08-368225. Epub 2011 Oct 26.

10.

Rapid screening of ASXL1, IDH1, IDH2, and c-CBL mutations in de novo acute myeloid leukemia by high-resolution melting.

Ibáñez M, Such E, Cervera J, Luna I, Gómez-Seguí I, López-Pavía M, Dolz S, Barragán E, Fuster O, Llop M, Rodríguez-Veiga R, Avaria A, Oltra S, Senent ML, Moscardó F, Montesinos P, Martínez-Cuadrón D, Martín G, Sanz MA.

J Mol Diagn. 2012 Nov;14(6):594-601. doi: 10.1016/j.jmoldx.2012.06.006. Epub 2012 Aug 25. Erratum in: J Mol Diagn. 2013 Mar;15(2):280.

PMID:
22929312
11.

Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.

Thol F, Damm F, Lüdeking A, Winschel C, Wagner K, Morgan M, Yun H, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Kanz L, Fiedler W, Kirchner H, Heil G, Krauter J, Ganser A, Heuser M.

J Clin Oncol. 2011 Jul 20;29(21):2889-96. doi: 10.1200/JCO.2011.35.4894. Epub 2011 Jun 13.

12.

Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.

Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE.

J Clin Oncol. 2010 Jun 1;28(16):2739-47. doi: 10.1200/JCO.2009.26.2501. Epub 2010 May 3.

13.

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, Cherry A, Vance G, Higgins RR, Ketterling RP, Gallagher RE, Litzow M, van den Brink MR, Lazarus HM, Rowe JM, Luger S, Ferrando A, Paietta E, Tallman MS, Melnick A, Abdel-Wahab O, Levine RL.

N Engl J Med. 2012 Mar 22;366(12):1079-89. doi: 10.1056/NEJMoa1112304. Epub 2012 Mar 14.

14.

Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.

Devillier R, Gelsi-Boyer V, Brecqueville M, Carbuccia N, Murati A, Vey N, Birnbaum D, Mozziconacci MJ.

Am J Hematol. 2012 Jul;87(7):659-62. doi: 10.1002/ajh.23211. Epub 2012 Apr 25.

15.

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K.

J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.

16.

Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.

Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrózek K, Radmacher MD, Kohlschmidt J, Nicolet D, Whitman SP, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Bloomfield CD.

J Clin Oncol. 2012 Mar 1;30(7):742-50. doi: 10.1200/JCO.2011.39.2092. Epub 2012 Jan 30.

17.

Gene mutation patterns in patients with minimally differentiated acute myeloid leukemia.

Kao HW, Liang DC, Wu JH, Kuo MC, Wang PN, Yang CP, Shih YS, Lin TH, Huang YH, Shih LY.

Neoplasia. 2014 Jun;16(6):481-8. doi: 10.1016/j.neo.2014.06.002. Epub 2014 Jul 10.

18.

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.

Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D.

J Hematol Oncol. 2012 Mar 21;5:12. doi: 10.1186/1756-8722-5-12. Review.

19.

IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.

Yamaguchi S, Iwanaga E, Tokunaga K, Nanri T, Shimomura T, Suzushima H, Mitsuya H, Asou N.

Eur J Haematol. 2014 Jun;92(6):471-7. doi: 10.1111/ejh.12271. Epub 2014 Mar 3.

PMID:
24443894
20.

Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.

Fernandez-Mercado M, Yip BH, Pellagatti A, Davies C, Larrayoz MJ, Kondo T, Pérez C, Killick S, McDonald EJ, Odero MD, Agirre X, Prósper F, Calasanz MJ, Wainscoat JS, Boultwood J.

PLoS One. 2012;7(8):e42334. doi: 10.1371/journal.pone.0042334. Epub 2012 Aug 9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk